Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy to strengthen US business


      Ranbaxy Laboratories, the country's biggest drug maker, is all set to strengthen its business in the US despite an import restriction on 30 of its medicines by the US Food and Drugs Authority.

      "Ranbaxy will increase its share of business in the US soon. We are responding to all queries from US FDA and will emerge as a stronger player in the world's biggest pharmaceutical market," Ranbaxy Chairman and Managing Director Malvinder Singh said. US sales account for 20 per cent of Ranbaxy’s $1.5-billion annual turnover.

      Speaking to reporters on the sidelines of the third India-Brazil-South Africa Business Meet here today, Singh said the company is confident of the quality and efficacy of its products in the US. The company is making alternative arrangements to ensure that all products, including the ones for which the company has limited market exclusivity, are launched in the US market without any delay, Singh added.

      The company, which is in the process of being taken over by Japan’s Daiichi Sankyo for $4.6 billion, expects to close the deal in the coming months. "The share transaction should be completed before December," Singh said. According to Singh, the post-transaction days will find Ranbaxy making strategic investments to strengthen its overseas business, including the US. The company has been facing severe regulatory scrutiny in the US after FDA allegedly found technical problems with the documentation processes and systems followed by the company in two of its Indian manufacturing units.

      The US FDA had even filed an information seeking motion against Ranbaxy in a US district court. The motion was withdrawn recently after the company submitted all data sought by the US FDA.

      October 16, 2008


      Share this Article!

    Back to top^